Compare Gilead Sciences, Inc. (GILD) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs PulteGroup, Inc. — how do they compare? Gilead Sciences, Inc. trades at $135.91 (market cap $163.51B), while PulteGroup, Inc. trades at $128.71 (market cap $23.89B). The key difference: Gilead Sciences, Inc. is far larger — about 6.8× PulteGroup, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | PHM | |
|---|---|---|
Market Cap | $163.51B | $23.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $142.56 |
52-Week Low | $108.22 | $108.65 |
Enterprise Value | $178.05B | $23.84B |
Dividend Yield | 2.49% | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
PulteGroup (PHM) trades at $127.11, up 2.05% today, with a bullish technical signal and strong profitability metrics including a 12.14% net margin. Recent earnings show mixed results with a Q3 2025 beat but subsequent misses, while cash flow trends improved in 2025. The stock is near its 52-week high of $144.50, reflecting resilience despite housing market headwinds from rising mortgage rates.
Outlook is cautiously optimistic with a consensus price target of $145.20 offering 14% upside, but risks include margin pressure from discounts and rate buydowns. Investment opportunity hinges on execution amid affordability challenges, with analyst sentiment balanced between buy and hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
